References
- Chau D, Becker DL, Coombes ME, et al. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J Med Econ 2012;15:3-14.
- Morawski JH, Prüfert A, van Engen A, et al. Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis. J Med Econ 2012;15:15-25.
- Treur M, Baca E, Bobes J, et al. The cost-effectiveness of paliperidone extended release in Spain. J Med Econ 2012;15:26-34.
- Armstrong E, Malone D, Bui C. Cost-effectiveness analysis of antimuscarinic agents for the treatment of overactive bladder. J Med Econ 2012;15:35-44. 1265638
- Barrios VA, Lobos L, Lobos J, et al. Cost-effectiveness analysis of rosuvastatin versus generic atorvastatin in Spain. J Med Econ 2012;15:45-54.
- Casciano R, Chulikavit M, Perrin A, et al. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. J Med Econ 2012;15:55-64.